Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, and sent shares of Septerna into the stratosphere.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

In response to a reporter's question, the official stated that "it would be fair to expect" that popular GLP-1 weight loss ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Eli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s ...

It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Despite lower-than-expected first-quarter revenues and a guidance cut for 2025, NVO stock price rose post its earnings release. This is because Novo Nordisk said on the first-quarter call that it ...

Healthcare stocks are generally more resilient in a challenging macro backdrop compared to stocks in other sectors. This is because the need for medicines and medical treatments i ...